BIOINFORMATICS TOOLS: ESSENTIAL FOR THE DEVELOPMENT AND DISCOVERY OF MEDICINES
Main Article Content
Abstract
Pharmaceutical research and development is a difficult, high-risk, time-consuming, and potentially lucrative process. Pharmaceutical corporations invest millions of dollars to get a medicine to market. A novel medication demands technical competence, human resources, and a large capital commitment. It also requires stringent adherence to laws on testing and manufacturing standards before a new medicine may be used in the general public; in fact, some drugs fail to enter the market. All of these considerations simply raise the expense of researching and developing a novel chemical entity. Bioinformatics/Tools in the drug design process has a favorable impact on the whole process and may speed up different processes of drug design while lowering costs and total time. The current note focuses on bioinformatics' importance in the drug development and research method.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
References
Iskar M, Zeller G, Zhao XM, van Noort V, Bork P (2012) Drug discovery in the age of systems biology: the
rise of computational approaches for data integration. Curr Opin Biotechnol 23(4): 609-616.
Whittaker P (2003) What is the relevance of bioinformatics to pharmacology? Trends Pharmacol Sci 24(8):
-439.
Ortega SS, Cara LC, Salvador MK (2012) In silico pharmacology for a multidisciplinary drug discovery process.
Drug Metabol Drug Interact 27(4): 199-207.
Speck Planche A, Cordeiro MN (2012) Computer aided drug design, synthesis and evaluation of new anticancer drugs. Curr Top Med Chem 12(24): 2703 2704.
Chen YP, Chen F (2008) Identifying targets for drug discovery using bioinformatics. Expert Opin Ther Targets
(4):383-389.
Katara P, Grover A, Kuntal H, Sharma V (2011) In silico prediction of drug targets in vibrio cholerae.
Protoplasma 248(4): 799-804.
Yamanishi Y, Kotera M, Kanehisa M, Goto S (2010) Drug-target interaction prediction from chemical, genomic
and pharmacological data in an integrated framework. Bioinformatics 26(12): 246-254.
Loh M, Soong R (2011) Challenges and pitfalls in the introduction of pharmacogenetics for cancer. Ann Acad
Med Singap 40(8): 369-374.
Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, et al. (2008) DrugBank: a knowledgebase for drugs,
drug actions and drug targets. Nucleic Acids Res 36: 901-906.
Zhu F, Shi Z, Qin C, Tao L, Liu X, et al. (2012) Therapeutic target database update 2012: a resource for
facilitating target-oriented drug discovery. Nucleic Acids Res 40: 1128-1136.
Kuhn M, Szklarczyk D, Franceschini A, Campillos M, von Mering C, et al. (2010) STITCH 2: an interaction
network database for small molecules and proteins. Nucleic Acids Res 38: 552-556.
Hecker N, Ahmed J, von Eichborn J, Dunkel M, Macha K, et al. (2012) Super target goes quantitative: update
on drug-target interactions. Nucleic Acids Res 40: 1113-1117.
Adams CP, Brantner VV (2010) Spending on new drug development. Health Econ 19(2): 130-141. 14. Tsaioun
K, Bottlaender M, Mabondzo A (2009) Alzheimer’s Drug Discovery Foundation ADDME avoiding drug
development mistakes early: central nervous system drug discovery perspective. BMC Neurol 9: S1.
Tamimi NA, Ellis P (2009) Drug development: from concept to marketing! Nephron Clin Pract. 113(3): 125-
Gilbert J, Henske P, Singh A (2003) Rebuilding Big Pharma’s Business Model. In vivo Business and Medicine
Report 21: 10.
Klein DB, Tabarrok A (2003) The drug discovery, development and approval process.
Collier R (2009) Rapidly rising clinical trial costs worry researchers. CMAJ 180(3): 277-278.
Liang BA, Mackey T (2011) Direct-to-consumer advertising with interactive internet media: global regulation
and public health issues. JAMA 305(8): 824-825.
Rawlins MD (2004) Cutting the cost of drug development? Nat Rev Drug Discov 3(4): 360-364.
Dickson M, Gagnon JP (2004) Key factors in the rising cost of new drug discovery and development. Nat Rev
Drug Discov 3(4): 417-429.
Meyers S, Baker A (2001) Drug discovery: an operating model for a new era. Nat Biotechnol. 19(8): 727-730.
Simoens S (2011) Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare
Dis 6: 42.
Lindpaintner K (2002) The impact of pharmacogenetics and pharmacogenomics on drug discovery. Nat Rev
Drug Discov 1(6): 463-469.
Shin J (2012) Clinical pharmacogenomics of warfarin and clopidogrel. J Pharm Pract 25(4): 428-438.
Dhaliwal B, Chen YW (2009) Computational resources for protein modelling and drug discovery applications.
Infect Disord Drug Targ 9(5): 557-562.
Du QS, Huang RB (2012) Recent progress in computational approaches to studying the M2 proton channel and
its implication to drug design against influenza viruses. Curr Protein Pept Sci 13(2): 205 210.